Table of Contents
ISRN Virology
Volume 2014 (2014), Article ID 351407, 11 pages
http://dx.doi.org/10.1155/2014/351407
Review Article

Interaction of Hepatitis C Viral Proteins with Cellular Oncoproteins in the Induction of Liver Cancer

Department of Microbiology, Immunology & Biochemistry, The University of Tennessee Health Science Center, Memphis, TN 38163, USA

Received 16 January 2014; Accepted 25 February 2014; Published 12 March 2014

Academic Editors: J. Choi and C. Torti

Copyright © 2014 Ramareddy V. Guntaka and Mythili K. Padala. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Hepatitis C virus Fact Sheet,” WHO Report 164, 2013.
  2. G. T. Strickland, “Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of latrogenic and biological factors,” Hepatology, vol. 43, no. 5, pp. 915–922, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Sievert, I. Altraif, H. A. Razavi et al., “A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt,” Liver International, vol. 31, no. 2, pp. 61–80, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. Z. Gellad, S. D. Reed, and A. J. Muir, “Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C,” Antiviral Therapy, vol. 17, pp. 1189–1199, 2012. View at Google Scholar
  5. D. Moradpour, F. Penin, and C. M. Rice, “Replication of hepatitis C virus,” Nature Reviews Microbiology, vol. 5, no. 6, pp. 453–463, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Moriishi and Y. Matsuura, “Exploitation of lipid components by viral and host proteins for hepatitis C virus infection,” Frontiers in Microbioloy, vol. 3, article 54, 2012. View at Google Scholar
  7. C. L. Murray and C. M. Rice, “Turning hepatitis C into a real virus,” Annual Review of Microbiology, vol. 65, pp. 307–327, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. B. M. Weiser and T. L. Tellinghuisen, “Structural biology of the hepatitis C virus proteins,” Drug Discovery Today: Technologies, vol. 9, pp. 195–204, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Moradpour and F. Penin, “Hepatitis C virus proteins: from structure to function,” Current Topics in Microbiology and Immunology, vol. 369, pp. 113–142, 2013. View at Google Scholar
  10. R. Bartenschlager, F.-L. Cosset, and V. Lohmann, “Hepatitis C virus replication cycle,” Journal of Hepatology, vol. 53, no. 3, pp. 583–585, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. C. M. Rice, “New insights into HCV replication: potential antiviral targets,” Topics in Antiviral Medicine, vol. 19, no. 3, pp. 117–120, 2011. View at Google Scholar · View at Scopus
  12. E. Herker and M. Ott, “Emerging role of lipid droplets in host/pathogen interactions,” Journal of Biological Chemistry, vol. 287, no. 4, pp. 2280–2287, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Bartenschlager, F. Penin, V. Lohmann, and P. André, “Assembly of infectious hepatitis C virus particles,” Trends in Microbiology, vol. 19, no. 2, pp. 95–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. N. A. Counihan, S. M. Rawlinson, and B. D. Lindenbach, “Trafficking of hepatitis C virus core protein during virus particle assembly,” PLoS Pathogens, vol. 7, no. 10, Article ID e1002302, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Chatel-Chaix, M. Baril, and D. Lamarre, “Y-box-binding protein 1 interacts with Hepatitis C virus NS3/4A and influences the equilibrium between viral RNA replication and infectious particle production,” Journal of Virology, vol. 85, no. 21, pp. 11022–11037, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. S. M. Horner and M. Gale Jr., “Regulation of hepatic innate immunity by hepatitis C virus,” Nature Medicine, vol. 19, pp. 879–888, 2013. View at Google Scholar
  17. B. De Chassey, V. Navratil, L. Tafforeau et al., “Hepatitis C virus infection protein network,” Molecular Systems Biology, vol. 4, article 230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. L. P. Tripathi, H. Kambara, Y.-A. Chen et al., “Understanding the biological context of NS5A-host interactions in HCV infection, a network-based approach,” Journal of Proteome Research, vol. 12, pp. 2537–2551, 2013. View at Google Scholar
  19. C. M. Walker, “Adaptive Immunity to the Hepatitis C Virus,” Advances in Virus Research, vol. 78, pp. 43–84, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Chatel-Chaix, M. A. Germain, A. Motorinalt et al., “A host YB-1 ribonculeoprotein complex is hijacked by hepatitis C virus for the control of NS3-dependent particle formation,” Journal of Virology, vol. 87, pp. 11704–11720, 2013. View at Google Scholar
  21. T. L. Tellinghuisen, K. L. Foss, and J. Treadaway, “Regulation of hepatitis C virion production via phosphorylation of the NS5A protein,” PLoS Pathogens, vol. 4, no. 3, Article ID e1000032, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Milward, J. Mankouri, and M. Harris, “Hepatitis C virus NS5A protein interacts with β-catenin and stimulates its transcriptional activity in a phosphoinositide-3 kinase-dependent fashion,” Journal of General Virology, vol. 91, no. 2, pp. 373–381, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. M. A. Skabkin, V. Evdokimova, A. A. M. Thomas, and L. P. Ovchinnikov, “The major messenger ribonucleoprotein particle protein p50 (YB-1) promotes nucleic acid strand annealing,” Journal of Biological Chemistry, vol. 276, no. 48, pp. 44841–44847, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Evdokimova, P. Ruzanov, M. S. Anglesio et al., “Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species,” Molecular and Cellular Biology, vol. 26, no. 1, pp. 277–292, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Colman, C. Le Berre-Scoul, C. Hernandez et al., “Genome-wide analysis of host mRNA translation during hepatitis C virus infection,” Journal of Virology, vol. 87, pp. 6668–6677, 2013. View at Google Scholar
  26. A. V. Ivanov, B. Bartosch, O. A. Smirnova et al., “HCV and oxidative stress in the liver,” Viruses, vol. 5, pp. 439–469, 2013. View at Google Scholar
  27. D. Selimovic, A. El-Khattouti, H. Ghozian et al., “Hepatitis C virus-related hepatocellular carcinoma: an insight into molecular mechanisms and therapeutic strategies,” World Journal of Hepatology, vol. 4, pp. 342–355, 2012. View at Google Scholar
  28. W.-L. Tsai and R. T. Chung, “Viral hepatocarcinogenesis,” Oncogene, vol. 29, no. 16, pp. 2309–2324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. A. J. Levine and M. Oren, “The first 30 years of p53: growing ever more complex,” Nature Reviews Cancer, vol. 9, no. 10, pp. 749–758, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. I. A. Eliseeva, E. R. Kim, S. G. Guryanov, L. P. Ovchinnikov, and D. N. Lyabin, “Y-box-binding protein 1 (YB-1) and its functions,” Biochemistry, vol. 76, no. 13, pp. 1402–1433, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Evdokimova, C. Tognon, T. Ng et al., “Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition,” Cancer Cell, vol. 15, no. 5, pp. 402–415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Khandelwal, M. K. Padala, J. Cox, and R. V. Guntaka, “The N-terminal domain of Y-box binding protein-1 induces cell cycle arrest in G2/M phase by binding to cyclin D1,” International Journal of Cell Biology, vol. 2009, Article ID 243532, 2009. View at Publisher · View at Google Scholar
  33. A. Lasham, C. G. Print, A. G. Woolley et al., “YB-1: oncoprotein, prognostic marker and therapeutic target?” Biochemical Journal, vol. 449, pp. 11–23, 2013. View at Google Scholar
  34. T. Okamoto, H. Izumi, T. Imamura et al., “Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression,” Oncogene, vol. 19, no. 54, pp. 6194–6202, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Kim, J. Choi, K. Heo et al., “Isolation and characterization of a novel H1.2 complex that acts as a repressor of p53-mediated transcription,” Journal of Biological Chemistry, vol. 283, no. 14, pp. 9113–9126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. L. A. Donehower, “Does p53 affect organismal aging?” Journal of Cellular Physiology, vol. 192, no. 1, pp. 23–33, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. S. K. Swamynathan, B. R. Varma, K. T. Weber, and R. V. Guntaka, “Targeted disruption of one allele of the Y-box protein gene, Chk-YB-1b, in DT40 cells results in major defects in cell cycle,” Biochemical and Biophysical Research Communications, vol. 296, no. 2, pp. 451–457, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. Z. H. Lu, J. T. Books, and T. J. Ley, “YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence,” Molecular and Cellular Biology, vol. 25, no. 11, pp. 4625–4637, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Uchiumi, A. Fotovati, T. Sasaguri et al., “YB-1 is important for an early stage embryonic development: neural tube formation and cell proliferation,” Journal of Biological Chemistry, vol. 281, no. 52, pp. 40440–40449, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. J. C. Kandala and R. V. Guntaka, “Cloning of Rous sarcoma virus enhancer factor genes. I. Evidence that RSV- EF-1 is related to Y-box (inverted CCAAT) binding proteins and binds to multiple motifs in the RSV enhancer,” Virology, vol. 198, no. 1, pp. 514–523, 1994. View at Google Scholar · View at Scopus
  41. A. Banerjee, K. Meyer, B. Mazumdar, R. B. Ray, and R. Ray, “Hepatitis C virus differentially modulates activation of Forkhead transcription factors and insulin-induced metabolic gene expression,” Journal of Virology, vol. 84, no. 12, pp. 5936–5946, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. A. D. Strosberg, S. Kota, V. Takahashi, J. K. Snyder, and G. Mousseau, “Core as a novel viral target for hepatitis C drugs,” Viruses, vol. 2, no. 8, pp. 1734–1751, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. C.-F. Kao, S.-Y. Chen, J.-Y. Chen, and Y.-H. W. Lee, “Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein,” Oncogene, vol. 23, no. 14, pp. 2472–2483, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Otsuka, N. Kato, K.-H. Lan et al., “Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability,” Journal of Biological Chemistry, vol. 275, no. 44, pp. 34122–34130, 2000. View at Google Scholar · View at Scopus
  45. R. B. Ray, R. Steele, K. Meyer, and R. Ray, “Hepatitis C virus core protein represses p21(WAF1/Cip1/Sid1) promoter activity,” Gene, vol. 208, no. 2, pp. 331–336, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Kanda, O. Yokosuka, and M. Omata, “Hepatitis C Virus and hepatocellular carcinoma,” Biology, vol. 2, pp. 304–316, 2013. View at Google Scholar
  47. H. Lerat, M. Honda, M. R. Beard et al., “Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus,” Gastroenterology, vol. 122, no. 2, pp. 352–365, 2002. View at Google Scholar · View at Scopus
  48. C. Pasquinelli, J. M. Shoenberger, J. Chung et al., “Hepatitis C virus core and E2 protein expression in transgenic mice,” Hepatology, vol. 25, no. 3, pp. 719–727, 1997. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Moriya, H. Fujie, Y. Shintani et al., “The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice,” Nature Medicine, vol. 4, no. 9, pp. 1065–1067, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Kamegaya, Y. Hiasa, L. Zukerberg et al., “Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis,” Hepatology, vol. 41, no. 3, pp. 660–667, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. D. R. McGivern and S. M. Lemon, “Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer,” Oncogene, vol. 30, no. 17, pp. 1969–1983, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Jahan, U. A. Ashfaq, S. Khaliq, B. Samreen, and N. Afzal, “Dual behavior of HCV Core gene in regulation of apoptosis is important in progression of HCC,” Infection, Genetics and Evolution, vol. 12, no. 2, pp. 236–239, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. N. Pavio and M. M. C. Lai, “The hepatitis C virus persistence: how to evade the immune system?” Journal of Biosciences, vol. 28, no. 3, pp. 287–304, 2003. View at Google Scholar · View at Scopus
  54. C. Bittar, S. Shrivastava, J. B. Chowdhury et al., “Hepatitis C virus NS2 protein inhibits DNA damage pathway by sequestering p53 to the cytoplasm,” PLoS ONE, vol. 8, Article ID e62581, 2013. View at Google Scholar
  55. H. C. Hwang and B. E. Clurman, “Cyclin E in normal and neoplastic cell cycles,” Oncogene, vol. 24, no. 17, pp. 2776–2786, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. J.-W. Cho, W.-K. Baek, S.-I. Suh et al., “Hepatitis C virus core protein promotes cell proliferation through the upregulation of cyclin E expression levels,” Liver, vol. 21, no. 2, pp. 137–142, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Deng, M. Nagano-Fujii, M. Tanaka et al., “NS3 protein of hepatitis C virus associates with the tumour suppressor p53 and inhibits its function in an NS3 sequence-dependent manner,” Journal of General Virology, vol. 87, no. 6, pp. 1703–1713, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. C.-K. Lai, K.-S. Jeng, K. Machida, Y.-S. Cheng, and M. M. C. Lai, “Hepatitis C virus NS3/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiation,” Virology, vol. 370, no. 2, pp. 295–309, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. N. Majumder, A. K. Ghosh, R. Steele, R. Ray, and R. B. Ray, “Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner,” Journal of Virology, vol. 75, no. 3, pp. 1401–1407, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. K.-H. Lan, M.-L. Sheu, S.-J. Hwang et al., “HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis,” Oncogene, vol. 21, no. 31, pp. 4801–4811, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. Ariumi, M. Kuroki, H. Dansako et al., “The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication,” Journal of Virology, vol. 82, no. 19, pp. 9639–9646, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. T. K. H. Scheel, J. Prentoe, T. H. R. Carlsen et al., “Analysis of functional differences between Hepatitis C Virus NS5A if Genotypes 1-7 in infectious cell culture systems,” PLoS Pathogens, vol. 8, Article ID e1002696, 2012. View at Google Scholar
  63. S. Raychaudhuri, V. Fontanes, B. Barat, and A. Dasgupta, “Activation of ribosomal RNA transcription by hepatitis C virus involves upstream binding factor phosphorylation via induction of cyclin D1,” Cancer Research, vol. 69, no. 5, pp. 2057–2064, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Das, R. Chattopadhyay, K. K. Bhakat et al., “Stimulation of NEIL2-mediated oxidized base excision repair via YB-1 interaction during oxidative stress,” Journal of Biological Chemistry, vol. 282, no. 39, pp. 28474–28484, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Jirawatnotai, Y. Hu, D. M. Livingston, and P. Sicinski, “Proteomic identification of a direct role for cyclin D1 in DNA damage repair,” Cancer Research, vol. 72, pp. 289–293, 2013. View at Google Scholar
  66. C. J. Sherr and J. M. Roberts, “Living with or without cyclins and cyclin-dependent kinases,” Genes and Development, vol. 18, no. 22, pp. 2699–2711, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. C. Homer, D. A. Knight, L. Hananeia et al., “Y-box factor YB1 controls p53 apoptotic function,” Oncogene, vol. 24, no. 56, pp. 8314–8325, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. K. I. M. Jong Kyong and J. Alan Diehl, “Nuclear cyclin D1: an oncogenic driver in human cancer,” Journal of Cellular Physiology, vol. 220, no. 2, pp. 292–296, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. J.-I. Kang, Y.-C. Kwon, and B.-Y. Ahn, “Modulation of the type i interferon pathways by culture-adaptive hepatitis C virus core mutants,” FEBS Letters, vol. 586, no. 9, pp. 1272–1278, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. H. Oshiumi, K. Sakai, M. Matsumoto, and T. Seya, “DEAD/H BOX 3 (DDX3) helicase binds the RIG-I adaptor IPS-1 to up-regulate IFN-β-inducing potential,” European Journal of Immunology, vol. 40, no. 4, pp. 940–948, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. K. Abdelmohsen and M. Gorospe, “RNA-binding protein nucleolin in disease,” RNA Biology, vol. 9, pp. 799–808, 2012. View at Google Scholar
  72. C.-K. Lai, K.-S. Jeng, K. Machida, and M. M. C. Lai, “Association of hepatitis C virus replication complexes with microtubules and actin filaments is dependent on the interaction of NS3 and NS5A,” Journal of Virology, vol. 82, no. 17, pp. 8838–8848, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. K. G. Chernov, A. Mechulam, N. V. Popova et al., “YB-1 promotes microtubule assembly in vitro through interaction with tubulin and microtubules,” BMC Biochemistry, vol. 9, no. 1, article 23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Janz, N. Harbeck, P. Dettmar et al., “Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1,” International Journal of Cancer, vol. 97, no. 3, pp. 278–282, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Basaki, F. Hosoi, Y. Oda et al., “Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells,” Oncogene, vol. 26, no. 19, pp. 2736–2746, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Yasen, K. Kajino, S. Kano et al., “The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma,” Clinical Cancer Research, vol. 11, no. 20, pp. 7354–7361, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. S. De Minicis, M. Marzioni, A. Benedetti et al., “New insights in hepatocellular carcinoma: from bench to bedside,” Annals of Translational Medicine, vol. 1, no. 2, article 15, 2013. View at Google Scholar
  78. F. Tacke, N. Kanig, A. En-Nia et al., “Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease,” BMC Cancer, vol. 11, pp. 185–191, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. Y. Wu, S. Yamada, H. Izumi et al., “Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer,” Journal of Surgical Oncology, vol. 105, no. 7, pp. 724–730, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. G. C. Prendergast, “Mechanisms of apoptosis by c-Myc,” Oncogene, vol. 18, no. 19, pp. 2967–2987, 1999. View at Publisher · View at Google Scholar · View at Scopus
  81. A. Lasham, E. Lindridge, F. Rudert, R. Onrust, and J. Watson, “Regulation of the human fas promoter by YB-1, Purα and AP-1 transcription factors,” Gene, vol. 252, no. 1-2, pp. 1–13, 2000. View at Publisher · View at Google Scholar · View at Scopus
  82. C. M. Shachaf, A. M. Kopelman, C. Arvanitis et al., “MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer,” Nature, vol. 431, no. 7012, pp. 1112–1117, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. L. C. Cobbold, L. A. Wilson, K. Sawicka et al., “Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1,” Oncogene, vol. 29, no. 19, pp. 2884–2891, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. L. Goyal, M. D. Muzumdar, and A. X. Zhu, “Targeting the HGF/c-MET pathway in hepatocellular carcinoma,” Clinical Cancer Research, vol. 19, pp. 2310–2318, 2013. View at Google Scholar
  85. B. W. Sutherland, J. Kucab, J. Wu et al., “Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells,” Oncogene, vol. 24, no. 26, pp. 4281–4292, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. Z. J. Zhou, Z. Dai, S. L. Zhou et al., “Overexpression of hnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma,” International Journal of Cancer, vol. 132, pp. 1080–1089, 2013. View at Google Scholar
  87. S. Bergmann, B. Royer-Pokora, E. Fietze et al., “YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification,” Cancer Research, vol. 65, no. 10, pp. 4078–4087, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. A. H. Davies, I. Barrett, M. R. Pambid et al., “YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification,” Oncogene, vol. 30, no. 34, pp. 3649–3660, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. X. Meng, P. Ezzati, and J. A. Wilkins, “Requirement of podocalyxin in TGF-beta induced epithelial mesenchymal transition,” PLoS ONE, vol. 6, no. 4, Article ID e18715, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. L. Akkari, D. Gregoire, F. Nicolas et al., “Hepatitis C viral protein NS5A induces EMT and participates in oncogenic transformation of primary hepatocyte precursors,” Journal of Hepatology, vol. 57, pp. 1021–1028, 2012. View at Google Scholar
  91. D. H. Lovett, S. Cheng, L. Cape, A. S. Pollock, and P. R. Mertens, “YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis,” Biochemical and Biophysical Research Communications, vol. 398, no. 3, pp. 482–488, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. D. J. Fraser, A. O. Phillips, X. Zhang et al., “Y-box protein-1 controls transforming growth factor-β1 translation in proximal tubular cells,” Kidney International, vol. 73, no. 6, pp. 724–732, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. M. A. Taylor, J. G. Parvani, and W. P. Schiemann, “The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-β in normal and malignant mammary epithelial cells,” Journal of Mammary Gland Biology and Neoplasia, vol. 15, no. 2, pp. 169–190, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Rauen, U. Raffetseder, B. C. Frye et al., “YB-1 acts as a ligand for notch-3 receptors and modulates receptor activation,” Journal of Biological Chemistry, vol. 284, no. 39, pp. 26928–26940, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. M. R. Finkbeiner, A. Astanehe, K. To et al., “Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells,” Oncogene, vol. 28, no. 11, pp. 1421–1431, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Battaglia, N. Benzoubir, S. Nobilet et al., “Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition,” PLoS ONE, vol. 4, no. 2, p. e4355, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. S. K. Bose, K. Meyer, A. M. Di Bisceglie, R. B. Ray, and R. Ray, “Hepatitis C virus induces epithelial-mesenchymal transition in primary hepatocytes,” Journal of Virology, vol. 86, pp. 13621–13628, 2012. View at Google Scholar
  98. M. P. Manns, J. G. McHutchison, S. C. Gordon et al., “Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial,” The Lancet, vol. 358, no. 9286, pp. 958–965, 2001. View at Publisher · View at Google Scholar · View at Scopus
  99. M. W. Fried, M. L. Shiffman, K. Rajender Reddy et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection,” New England Journal of Medicine, vol. 347, no. 13, pp. 975–982, 2002. View at Publisher · View at Google Scholar · View at Scopus
  100. J. Zhong, P. Gastaminza, J. Chung et al., “Persistent hepatitis C virus infection in vitro: coevolution of virus and host,” Journal of Virology, vol. 80, no. 22, pp. 11082–11093, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. S. Li, E. J. Gowans, C. Chougnet, M. Plebanski, and U. Dittmer, “Natural regulatory T cells and persistent viral infection,” Journal of Virology, vol. 82, no. 1, pp. 21–30, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. S. L. Fishman and A. D. Branch, “The quasispecies nature and biological implications of the hepatitis C virus,” Infection, Genetics and Evolution, vol. 9, no. 6, pp. 1158–1167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. P. Farci, “New insights into the HCV quasispecies and compartmentalization,” Seminars in Liver Disease, vol. 31, no. 4, pp. 356–374, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. A. Más, C. López-Galíndez, I. Cacho, J. Gómez, and M. A. Martínez, “Unfinished stories on viral quasispecies and darwinian views of evolution,” Journal of Molecular Biology, vol. 397, no. 4, pp. 865–877, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. X. Forns, R. H. Purcell, and J. Bukh, “Quasispecies in viral persistence and pathogenesis of hepatitis C virus,” Trends in Microbiology, vol. 7, no. 10, pp. 402–410, 1999. View at Publisher · View at Google Scholar · View at Scopus
  106. P. Farci, K. Wollenberg, G. Diaz et al., “Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 36, pp. 14562–14567, 2012. View at Google Scholar
  107. J. -M. Pawlotsky, “Drug resistance: prevalence and clinical implications during the treatment of chronic hepatitis C infection,” Clinical Liver Disease, vol. 1, no. 2, pp. 58–61, 2012. View at Google Scholar
  108. J.-M. Pawlotsky, “NS5A inhibitors in the treatment of hepatitis C,” Journal of Hepatology, vol. 59, pp. 375–382, 2013. View at Google Scholar
  109. K. Machida, J.-C. Liu, G. McNamara, A. Levine et al., “Hepatitis C virus causes uncoupling of mitotic checkpoint and chromosomal polyploidy through the Rb pathway,” Journal of Virology, vol. 83, no. 23, pp. 12590–12600, 2009. View at Google Scholar
  110. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. R. C. Bargou, K. Jürchott, C. Wagener et al., “Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression,” Nature Medicine, vol. 3, no. 4, pp. 447–450, 1997. View at Publisher · View at Google Scholar · View at Scopus
  112. P. A. Futreal, L. Coin, M. Marshall et al., “A census of human cancer genes,” Nature Reviews Cancer, vol. 4, no. 3, pp. 177–183, 2004. View at Google Scholar · View at Scopus
  113. C. Greenman, P. Stephens, R. Smith, and G. L. Dalgliesh, “Patterns of somatic mutation in human cancer genome,” Nature, vol. 446, pp. 153–158, 2007. View at Google Scholar
  114. M. Pellerin, Y. Lopez-Aguirre, F. Penin, D. Dhumeaux, and J.-M. Pawlotsky, “Hepatitis C virus quasispecies variability modulates nonstructural protein 5A transcriptional activation, pointing to cellular compartmentalization of virus-host interactions,” Journal of Virology, vol. 78, no. 9, pp. 4617–4627, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. J. Lara, G. Xia, M. Purdy, and Y. Khudyakov, “Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy,” Journal of Virology, vol. 85, no. 7, pp. 3649–3663, 2011. View at Publisher · View at Google Scholar · View at Scopus